Anne-sophie S. Carret
Montreal, QC, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
Exposure-safety Markov modeling of ocular adverse events in patient populations treated with tisotumab vedotin.
Journal: Journal of pharmacokinetics and pharmacodynamics
Published: November 04, 2024
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 12, 2024
A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab.
Journal: Future oncology (London, England)
Published: November 23, 2023
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 27, 2023
Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 30, 2022
Langerhans Cell Histiocytosis With Vertebral Involvement Diagnosed and Treated Over the Last 15 Years in a Single Canadian Pediatric Academic Institution.
Journal: Journal of pediatric hematology/oncology
Published: March 12, 2019
A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma.
Journal: Cancer
Published: July 30, 2018
A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma.
Journal: Investigational new drugs
Published: June 21, 2018
Survival Following Tumor Recurrence in Children With Medulloblastoma.
Journal: Journal of pediatric hematology/oncology
Published: February 13, 2018
Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome.
Journal: Acta neuropathologica
Published: June 16, 2017
Embryonal tumors in Canadian children less than 36 months of age: results from the Canadian Pediatric Brain Tumor Consortium (CPBTC).
Journal: Journal of neuro-oncology
Published: October 22, 2016
Atypical teratoid rhabdoid tumor in the first year of life: the Canadian ATRT registry experience and review of the literature.
Journal: Journal of neuro-oncology
Published: September 08, 2016
Last Updated: 09/26/2026